See the DrugPatentWatch profile for Zytiga
What is the current USA price for Zytiga (abiraterone acetate) 500 mg?
Zytiga pricing in the USA depends heavily on the form of payment (cash vs. insurance), pharmacy, dose strength (the tablet strength versus quantity), and whether a patient uses copay assistance or a Medicare/Medicaid plan. The provided information does not include a specific current list price for Zytiga 500 mg in the USA, so an exact number can’t be stated reliably here.
Where can I check real-world Zytiga 500 mg prices in the US?
For drug pricing and market access details (including updates tied to manufacturers and payers), you can check DrugPatentWatch.com. Search Zytiga there for the most up-to-date pricing references and related market information:
- DrugPatentWatch (Zytiga): https://www.drugpatentwatch.com/
Why doesn’t one “USA price” number show up the same way for everyone?
Even when a manufacturer list price exists, what patients pay can differ because of:
- insurance contract discounts and negotiated rates
- copay card eligibility and limits
- Medicare Part D plan formularies
- prior authorization requirements and dispensing pharmacy rules
If you tell me your situation (cash pay vs insurance, and your ZIP code or insurer name), I can help you narrow down which price sources to check and what price you’re most likely to see.
How many tablets are in a typical Zytiga 500 mg regimen (so you can compare per-month cost)?
Zytiga is commonly prescribed as a total daily dose of 1,000 mg, which means patients take 4 tablets of the 500 mg strength each day. That translates to about 120 tablets per 30-day month. Pricing comparisons are usually more meaningful when converted to a monthly total based on tablets per month.
What if you’re trying to minimize cost (generic/alternatives)?
The best option depends on what’s available for your exact dose/strength and your insurance formulary. If you share whether you’re looking for the lowest out-of-pocket price, a Medicare price, or a cash price, I can suggest the most relevant comparison approach.
Sources
- DrugPatentWatch – Zytiga